New Cancer Therapy Could Give Hope To 'Incurable' Patients
A new experimental treatment has achieved what chemotherapy and bone marrow transplants have failed to do: put chronic, relapsing blood cancers into remission. What's more, it uses the body's own natural defense system to attack these cancerous growths. The treatment involves T cells, a type of immune cell that works as your body's own personal S.W.A.T. team to detect, surround, and destroy foreign invaders like bacteria or viruses. Historically, cancerous cells have grown too fast for T cells to mount an effective defense, and they can also trick T cells into thinking that they’re a healthy part of the body as opposed to a cancerous growth that needs to be stopped. But in experimental treatments at the Fred Hutchinson Cancer Research Center in Seattle, initial evidence shows Dr. Stanley Riddell has successfully trained these T cells to better recognize and eliminate cancer cells in a short time span, allowing cancer to go into remission. Specifically, he extracted a person's T cells in order to prime them to recognize the type of cancer that is affecting the patient, allowing these primed T cells to attack the growth while sparing healthy cells and tissue. The results Riddell's preliminary findings on the success of T cell therapy to cure previously terminal cases of cancer made a stir at an annual meeting of the American Association for the Advancement of Science in Washington, D.C. on Sunday because of his eye-popping results: 93 perc...
ConclusionThis endoscopy-based study revealed the most common histology of benign SB tumors were hamartoma and adenoma, and malignant ones were lymphomas, GISTs, adenocarcinomas and metastatic cancers. Most of them were male gender, except for GISTs, and with proximal location, except for lymphomas. Further large-scale investigation efforts are warranted to elucidate the epidemiology of SB tumors.
ConclusionsThese findings linked the anti-tumor properties of PE with the immune microenvironment to present a reliable basis for the future practical application of PE in cervical cancer as a novel and pharmacologically safe immunotherapy strategy.Graphical abstract
ConclusionsThe experimental results from the pharmacological research enable the validation of their traditional uses in several of the groups of diseases in the countries of origin and reveal these plants to be a valuable source for therapeutic molecules. However, more toxicity assays and clinical trials would be necessary to establish optimal and safe doses of consumption on the application of these medicinal plants.Graphical abstract
In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Conclusions: AEE protected against 5-Fu-induced intestinal mucositis (IM) in mice through mechanisms that involved in promoting the enterocyte proliferative activity, maintaining the integrity of tight junction proteins, inhibiting oxidative stress and ameliorating the inflammatory disturbances. Accordingly, A. agallocha may be a promising therapeutic candidate used for the prevention of IM during cancer chemotherapy.Graphical abstractThe results of this study gave a scientific support for the protection of AEE on 5-Fu-induced IM in mice through mechanisms that involved in promoting the enterocyte proliferative activity, m...
Publication date: Available online 20 July 2018Source: American Heart JournalAuthor(s): Nuccia Morici, Fabrizio Oliva, Silvia Ajello, Miriam Stucchi, Alice Sacco, Manlio Gianni Cipriani, Michele De Bonis, Andrea Garascia, Maria Pia Gagliardone, Giulio Melisurgo, Claudio Francesco Russo, Carlo La Vecchia, Maria Frigerio, Federico PappalardoManagement of acute decompensated heart failure (ADHF) patients presenting with cardiogenic shock (CS) is not straightforward, as few data are available from clinical trials. Stabilization before left ventricle assist device (LVAD) or heart transplantation (HTx) is strongly advocated, as ...
Publication date: Available online 18 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kian J. Rahbari, Jason D. Nosrati, Tanya M. Spektor, James R. Berenson
ConclusionAlthough patients with MYC-R lymphoma have been reported to be at high risk of primary treatment failure, this was not predicted by iPET+ results. Thus, the iPET result should not be used to guide changes in front-line or consolidative therapy for these patients.
Publication date: Available online 20 July 2018Source: Cancer EpidemiologyAuthor(s): E.E. Jedy-Agba, E.O. Dareng, S.N. Adebamowo, M. Odutola, E.A. Oga, F. Igbinoba, T. Otu, E. Ezeome, F. Bray, R. Hassan, C.A. Adebamowo
Publication date: Available online 20 July 2018Source: Cancer GeneticsAuthor(s): Daja Šekoranja, Emanuela Bostjančič, Vladka Salapura, Blaž Mavčič, Jože PižemAbstractAneurysmal bone cyst (ABC) is a benign but locally aggressive, mostly pediatric neoplasm, with characteristic USP6 gene rearrangement that distinguishes it from a secondary ABC and other primary bone tumors. With the advent of next-generation sequencing (NGS) technology, several hitherto unknown USP6 fusion partners have been identified in ABC. Accordingly, we present a case of an 18-year-old male with a solid sub-periosteal primary ABC in the di...
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Colon Cancer | Colorectal Cancer | Environmental Health | Health | Hodgkin's Disease | Hospitals | Immunotherapy | Learning | Leukemia | Lung Cancer | Lung Transplant | Lymphoma | Non-Hodgkin's Lymphoma | Science | Study | Transplant Surgery | Transplants | Universities & Medical Training | Websites